SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2016 / Cilt: 46 - Sayı: 2

The role of 18F-FDG PET-CT in the detection of unknown primary malignancy: a retrospective study

Fatma Suna KIRAÇ
Olga YAYLALI
Doğangün YÜKSEL
Pages
474–482
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We propose that 18F-FDG PET/CT imaging may help to accurately detect malignant lesions in patients with unknown primary tumors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: This study aimed to retrospectively evaluate the role of 18F-FDG PET/CT imaging in the detection of unknown primary tumor sites in patients with a suspicious malignancy.
📊
Key Findings & Data:Materials and methods: We retrospectively examined the 18F-FDG PET/CT images of 50 unknown primary malignancy patients.
💡
Conclusion & Impact:We propose that 18F-FDG PET/CT imaging may help to accurately detect malignant lesions in patients with unknown primary tumors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: This study aimed to retrospectively evaluate the role of 18F-FDG PET/CT imaging in the detection of unknown primary tumor sites in patients with a suspicious malignancy. Materials and methods: We retrospectively examined the 18F-FDG PET/CT images of 50 unknown primary malignancy patients. The malignancy of the lesions with increased 18F-FDG uptake on PET images was defined by interpreting the nondiagnostic CT images that were obtained with the PET study. The primary tumor site was decided according to the combined PET/CT findings, and the results were subsequently confirmed with a histopathological examination. Results: Fifty patients (29 M; 21 F) aged 18 85 years were included in the study. The sample included 32 malignant and 18 benign lesions according to the histopathological evaluation. 18F-FDG PET/CT study accurately identified malignant lesions in 28 (average SUVmax ± SD: 8.27 ± 7.22) and benign lesions in 12 (average SUVmax ± SD: 3.63 ± 3.07) patients; these findings were histopathologically confirmed. PET/CT correctly detected the primary tumor site in 16 (50%) of 32 patients. Conclusion: 18F-FDG-PET/CT identified the primary tumor site well in 50% of our cases. We propose that 18F-FDG PET/CT imaging may help to accurately detect malignant lesions in patients with unknown primary tumors.

🔖

Cite This Article

KIRAÇ, F. S., YAYLALI, O., YÜKSEL, D. (2022). The role of 18F-FDG PET-CT in the detection of unknown primary malignancy: a retrospective study. Turkish Journal of Medical Sciences, Cilt: 46 - Sayı: 2, 474–482. https://ajindex.com/articles/610667

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of unknown primary. Eur J Cancer 2003; 39: 1990–2005
  2. Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol 2007; 46: 592–601
  3. Chorost MI, Lee MC, Yeoh CB, Molina M, Ghosh BC. Unknown primary. J Surg Oncol 2004; 87: 191–203
  4. Le Chevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielmann M, Rouesse J. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med 1988; 148: 2035–2039
  5. Naresh KN. Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site? A hypothesis. Med Hypotheses 2002; 59: 357–360
  6. Kaya AO, Coskun U, Unlu M, Akdemir UO, Ozdemir NY, Zengin N, Benekli M, Yildiz R, Yaman E, Ozturk B et al. Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin. Asian Pac J Cancer Prev 2008; 9: 683–686
  7. Ambrossini V, Nanni C, Rubello D, Moretti A, Battista G, Castellucci P, Farsad M, Rampin L, Fiorentini G, Franchi R et al. 18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin. Radiol Med 2006; 111: 1146–1155
  8. Pelosi E, Pennone M, Deandreis D, Douroukas A, Mancını M, Bisi G. Role of whole body positron emission tomography/ computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging 2006; 50: 15–22
  9. Delgado-Bolton RC, Fernandez-Perez C, Gonzales-Mate’ A, Carreras JL. Meta-analysis of the performance of 18F-FDG PET in primary tumour detection in unknown primary tumors. J Nucl Med 2003; 44: 1301–1314
  10. Gutzeit A, Antoch G, Kuhl H, Egelhof T, Fischer M, Hauth E, Goehde S, Bockisch A, Debatin J, Freudenberg L. Unknown primary tumors: detection with dual-modality PET/CT– initial experience. Radiology 2005; 234: 227–234
  11. Reske SN, Kotzerke J. FDG PET for clinical use: results of the 3rd German Interdisciplinary Concensus Conference, “OncoPET III,” 21 July and 19 September 2000. Eur J Nucl Med 2001; 28: 1707–1723
  12. Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol 2009; 19: 731–744
  13. Bohuslavizki KH, Klutmann S, Kroger S, Sonnemann U, Buchert R, Werner JA, Mester J, Clausen M. FDG PET detection of unknown